Pfizer Animal Health Launches the First Spray Vaccine Against E. Coli for Poultry in the European Union
Paris, 03 October 2012 - Pfizer Animal Health announces the launch of Poulvac E coli, the first spray vaccine against avian pathogenic Escherichia coli (APEC) for the poultry industry to be approved in the European Union.
This new vaccine is based on a European E. coli isolate, and has been shown to provide a broad protection against field infections found in the region. It can be administered from one day of age, and studies have shown that it generates a strong immune response that reduces mortality for up to 12 weeks1-4. The vaccine has a zero-day withdrawal period. Revaccination depending on local field pressure and risk assessment can be considered in consultation with a veterinarian.
This vaccine represents the first effective vaccine that can be administered en masse to birds to prevent often devastating infections with E. coli in poultry. It represents an innovation for the market as the first ever product to be administered by coarse spray.
The new product provides a new preventative option for both producers and veterinarians, as Erik Uyttebroek, marketing director at Pfizer Poultry EuAfME, explains:
“The layer sector has access to very few effective antibiotics that do not cause violative residues in eggs. In fact, in some countries there is no licensed anti-infective at all that can be used in layers to treat diseased birds. For these businesses, Poulvac E coli will provide an effective means of controlling APEC and improving animal health and welfare.”
Mr Uyttebroek believes the new vaccine will be particularly useful for protecting high value birds, such as replacement layers and breeders, which have a relatively long life span.
“This is the first modified live vaccine against APEC to be launched in the EU, and is the first that you administer directly to the birds you want to protect, rather than vaccinating the breeders and relying on maternal antibodies.”
“Some producers have tried to use auto-vaccines to protect their flocks against APEC, but this means injecting birds individually, which is far from ideal. Plus, these vaccines can also cause unwanted reactions in some birds. Poulvac E coli represents an effective and less labour intensive alternative,” says Mr Uyttebroek.
Poulvac E coli has been available to US poultry producers for more than two years and is also licensed in a number of Latin American countries.
APEC is an opportunistic pathogen which usually produces infections in birds that are immunocompromised or stressed, for example as a result of a primary respiratory infection. It is recognised as a significant cause of financial loss to the poultry industry worldwide.
1. Data on file, Study Report No. PPH-0006, Pfizer Inc.
2. Data on file, Study Report No. PL-178-2007, Pfizer Inc.
3. Data on file, Study Report No. TIA 23663, Pfizer Inc.
4. Data on file, Study Report No. PL-198-2007, Pfizer Inc.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc., is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. For more than 60 years, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them. To learn more, visit www.pfizeranimalhealth.com.
For further information, Contact:
Garnett Keeler PR
Tel: +44 20 8647 4467